Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027497 (nausea)
 23,468 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

To define the maximum tolerated dose and to study whether recombinant human interleukin-3 (rhIL-3) reduced chemotherapy-induced neutropenia and thrombocytopenia, 20 chemotherapy-naive patients with advanced ovarian cancer eligible for treatment with 6 cycles of carboplatin-cyclophosphamide every 4 weeks (day 1) were entered in a phase I/II open, single-center trial. Cohorts of five patients received during 7 days 1, 5, 10, or 15 micrograms/kg/d rhIL-3 (days 5 through 11) in cycles 1, 3, and 5 by continuous intravenous (IV) infusion or once daily subcutaneous (SC) administration. In control cycles 2, 4, and 6, no rhIL-3 was administered. rhIL-3 significantly increased the recovery of leukocyte, neutrophil, and platelet counts, especially at 5, 10, and 15 micrograms/kg rhIL-3. rhIL-3 also increased basophil, eosinophil, monocyte, and lymphocyte counts at this dose steps. Effects on reticulocytes were limited. No difference in efficacy between SC and IV rhIL-3 treatment was found. Chemotherapy postponement for insufficient bone marrow recovery was necessary in 22 of 45 control cycles versus 2 of 49 rhIL-3 cycles (P less than .001). Platelet transfusions were required in 7 of 45 control cycles versus 3 of 50 rhIL-3 cycles (P less than .5). rhIL-3 up to 10 micrograms/kg/d could be administered without severe side effects. At 15 micrograms/kg/d, rhIL-3 headache was dose-limiting. Other side effects were fever, flu-like symptoms, nausea, skin rash, flushing, facial erythema, and urticaria. Liver toxicity occurred in rhIL-3 and control cycles. rhIL-3 slightly increased tumor necrosis factor alpha, C-reactive protein, and serum amyloid A plasma levels, whereas no effect on IL-6 plasma levels was observed. rhIL-3 administered SC appears to be an interesting hematopoietic growth factor for reduction of chemotherapy-induced myelotoxicity.
 ...
PMID:Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. 151 36

To define the toxicity profile of recombinant human interleukin-6 (rhIL-6) and to study its effect on hematopoiesis, biochemical parameters and other cytokines, rhIL-6 was administered in a phase I-II study to 20 patients with breast carcinoma or nonsmall cell lung cancer. RhIL-6 doses were 0.5, 1.0, 2.5, 5.0, 10, and 20 micrograms/kg/d, with at least three patients per dose level. RhIL-6 was administered 24 hours by continuous intravenous infusion followed by subcutaneous (SC) administration for 6 days, partly on an outpatient basis. RhIL-6-related side effects were fever, headache, myalgia, and local erythema. Starting at 2.5 micrograms/kg/d, these side effects were compounded by nausea, reversible increase in liver enzymes, and anemia. Flu-like symptoms were controllable up to and including 10 micrograms rhIL-6/kg/d with acetaminophen. RhIL-6 increased platelet counts with a decrease in mean platelet volume and increased leukocytes caused by neutrophil, monocyte, and lymphocyte increase, with an increase in T cells and natural killer cells at 1.0 and 2.5 micrograms rhIL-6/kg/d. The reversible anemia was characterized by a decrease in serum iron, and an increase in ferritin and erythropoietin without reticulocytosis. RhIL-6 reduced total cholesterol levels and a dose-related increase of C-reactive protein and serum amyloid A plasma levels was observed. Serum IL-6 levels were increased, especially at 10 and 20 micrograms/kg/d, whereas no change in IL-1 beta and tumor necrosis factor alpha levels was observed. RhIL-6 can be administered with controllable side effects in this setting, up to and including a SC dose of 10 micrograms/kg/d on an outpatient basis, and has a promising stimulating effect on leukopoiesis and thrombopoiesis.
 ...
PMID:Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. 806 39

Gastrointestinal involvement by amyloidosis is common, but large clinicopathological studies specifically addressing gastric amyloidosis are lacking. Seventy-nine patients with biopsy-proven, gastric amyloidosis were identified by a retrospective review of our pathology archives, from 2007 to 2013. Amyloid typing was performed by laser microdissection/mass spectrometry (in 44 patients), immunohistochemistry, immunofluorescence, and/or genetic testing. The median age at diagnosis was 62years, with 61% being males. The amyloid was derived from immunoglobulin light chain (67%), transthyretin (ATTR) (18%), serum amyloid A (9%), and apolipoprotein A1 (3%). When other gastrointestinal sites were biopsied, amyloid was demonstrated in the small bowel (89%), colon (81%), and esophagus (33%). The most common gastrointestinal manifestations were weight loss (37%), abdominal pain/dyspepsia (23%), and nausea/vomiting (23%). Endoscopic findings included normal (35%), erythema (33%), erosions (18%), and nodularity (15%) and were not related to amyloid type. No case showed gastric lymphoma. The most common location of amyloid was the muscularis mucosae regardless of the type of amyloid. Lamina propria involvement was less frequent in ATTR than other types. In 22% of patients, the first diagnosis of amyloid was based on the gastric biopsy. Patients' survival at 3years was 60% and was not different by type of amyloid. Our study shows that light-chain amyloidosis is the most common form of gastric amyloidosis, followed by ATTR. Type of amyloid cannot be predicted based on clinical or endoscopic findings, and therefore, biopsy with amyloid typing, preferably by laser microdissection/mass spectrometry, is critical to establish the correct diagnosis, prognosis, and appropriate treatment.
...
PMID:Gastric amyloidosis: clinicopathological correlations in 79 cases from a single institution. 2564 8

Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA) syndrome is the most common autoinflammatory disorder among children in many parts of the world and an important differential diagnosis in children presenting with recurrent fever episodes. Commonly, PFAPA has an onset under the age of 5 years. Fever episodes in PFAPA usually last 3-6 days and are associated with one or more of the cardinal symptoms aphthous stomatitis, pharyngitis and cervical adenitis. The fever episodes typically recur with an interval of 3-6 weeks, often with a striking regularity. During the episodes, the patient has elevated inflammatory variables such as CRP and serum amyloid A (SAA) and may sometimes have additional symptoms such as abdominal pain, nausea and leg pain. Between the fever episodes, the patient is typically free of symptoms with normalized inflammatory variables and grows normally. Awareness and recognition of PFAPA is key to providing the patient with adequate treatment and avoiding misdiagnosis.
 ...
PMID:[PFAPA syndrome - An important differential diagnosis in children with recurrent fever]. 3166 Nov 47